A comprehensive expert synthesis, meticulously compiled by an international consortium of over 25 leading scientists from institutions including the University of Oslo (UiO) and Akershus University Hospital (Ahus), has illuminated the profound implications of nicotinamide adenine dinucleotide (NAD+) in the pursuit of healthier aging and the mitigation of debilitating neurological conditions. Published in the esteemed journal Nature Aging, this collaborative review consolidates cutting-edge research and clinical perspectives, underscoring a burgeoning global endeavor to harness the restorative power of this vital biomolecule. The collective insights presented paint a compelling picture of NAD+‘s multifaceted role in cellular vitality and its potential as a therapeutic target for age-associated diseases, including Alzheimer’s and Parkinson’s.
At its core, NAD+ functions as an indispensable coenzyme, orchestrating a symphony of critical cellular processes. Often described as the conductor of cellular energy production, it is intrinsically involved in the metabolic pathways that convert nutrients into usable energy, thereby fueling every biological function. Beyond its energetic role, NAD+ is a master regulator of DNA repair mechanisms, safeguarding the integrity of our genetic blueprint against the cumulative damage incurred over time. Furthermore, it plays a pivotal part in maintaining the optimal functioning and survival of cells, acting as a linchpin for overall cellular health. However, a natural and pervasive phenomenon of aging is the progressive diminution of NAD+ levels within the body. This age-induced decline has been extensively correlated with a spectrum of functional impairments, ranging from cognitive deficits and memory disturbances to a general erosion of physical vigor and an amplified susceptibility to a host of age-related pathologies.
The strategic manipulation of NAD+ metabolism presents a tantalizing prospect for not only delaying the onset of age-related functional deterioration but also for potentially warding off premature aging syndromes, according to Dr. Jianying Zhang, a principal investigator in this groundbreaking review. Nevertheless, Dr. Zhang articulated a crucial caveat: realizing the full therapeutic promise of NAD+ hinges on a more profound understanding of optimal dosing regimens, the establishment of long-term safety profiles, and the nuanced recognition of individual variations in cellular responses to strategies aimed at augmenting NAD+ levels. This intricate interplay between molecular biology and individual physiology necessitates careful, evidence-based exploration before widespread clinical application can be confidently embraced.
The review meticulously scrutinizes a substantial body of preclinical investigations and emerging clinical trials that have explored diverse methodologies for elevating endogenous NAD+ concentrations. A prominent class of compounds under intense investigation are vitamin-like molecules, specifically nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which serve as precursors to NAD+. Early findings from these studies have been remarkably encouraging, with preliminary clinical trials reporting notable improvements in cognitive function, enhancements in motor skills, and positive impacts on metabolic health markers in participants. These initial successes have fueled optimism within the scientific community, suggesting a tangible pathway towards improving quality of life in aging populations.
Despite these promising early indicators, the researchers underscore the imperative for larger-scale, long-duration clinical studies involving human subjects across a broad spectrum of diseases. Such rigorous investigations are deemed essential to conclusively validate the efficacy and generalizability of these NAD+-boosting approaches across different pathological contexts and patient demographics. The transition from promising laboratory results to robust clinical treatments requires a methodical and evidence-driven approach, ensuring that interventions are both safe and consistently effective.
The recent publication emerges amidst a period of intensified scientific and public fascination with NAD+-centric interventions. A global surge in clinical trials is actively underway, including significant research initiatives within Norway, dedicated to evaluating the therapeutic potential of NAD+ precursors like NR and NMN. Concurrently, these compounds have found their way into a rapidly expanding global dietary supplement market, fostering considerable discussion and, at times, debate regarding the comparative efficacy of various available options and the extent to which findings derived from animal models can be reliably extrapolated to human physiology. This burgeoning market underscores the public’s keen interest, but also highlights the critical need for scientifically grounded guidance.
"It is precisely this confluence of burgeoning interest, rapid market development, and ongoing scientific inquiry that compels us to disseminate an expert consensus at this juncture," explained Dr. Evandro Fei Fang-Stavem, the senior author and the distinguished head of the Fang Lab at UiO and Ahus. He emphasized that while NAD+ is intrinsically fundamental to life, the field is presently characterized by a degree of ambiguity and conflicting information concerning the optimal NAD+-boosting supplements and their appropriate utilization. The meticulously crafted article aims to consolidate the existing scientific evidence, thereby furnishing a clear and authoritative scientific roadmap to guide both ongoing research endeavors and the prospective clinical implementation of NAD+-based strategies. This synthesis serves as a beacon, illuminating the path forward through the complex landscape of NAD+ research.
Professor Torbjørn Omland, MD, PhD, MPH, Deputy Head of the Institute of Clinical Medicine and a co-author of the review, highlighted a significant knowledge deficit concerning NAD+ and its clinical ramifications, affecting both basic scientists and practicing clinicians. He posited that this comprehensive review paper offers the most current expert perspective for individuals engaged in and interested in the field of NAD+ research. Furthermore, he anticipates that the review will furnish invaluable information pertinent to a multitude of NAD+-focused clinical trials targeting a diverse array of clinical conditions, including significant neurological and cardiovascular disorders. This bridging of knowledge gaps is crucial for accelerating scientific progress and therapeutic development.
The authors collectively and emphatically underscore the critical necessity for enhanced global collaboration and the execution of more stringent, well-designed clinical trials, even as NAD+-based supplements and therapies undergo widespread investigation. These collaborative and rigorous scientific undertakings are not merely desirable but are deemed absolutely essential for the successful translation of promising early-stage findings into safe, effective, and widely accessible treatments for the multifaceted challenges of aging and its associated diseases. The path forward requires a united, evidence-driven approach to unlock the full therapeutic potential of NAD+ for the betterment of human health.
The esteemed review benefits from the contributions of numerous Norwegian researchers, including Sofie Lautrup (UiO and Ahus), Hilde Loge Nilsen (OUS), Leiv Otto Watne (Ahus and UiO), Geir Selbæk (UiO and Norwegian National Centre for Ageing and Health), Mathias Ziegler (UiB), Ole-Bjørn Tysnes (UiB), and Charalampos Tzoulis (UiB). The international scope of this vital research is further amplified by the inclusion of authors affiliated with prestigious institutions worldwide, such as the University of Copenhagen (Denmark), Chiba University (Japan), Harvard Medical School (USA), and the Buck Institute for Research on Aging (USA), underscoring the global nature of this critical scientific inquiry.
About the Author
